What are the contraindications for taking capmatinib?

Capmatinib (Capmatinib) is a targeted therapy drug mainly used to treat METexon14 skipping mutations ( patients with non-small cell lung cancer (NSCLC). Although capmatinib provides an effective treatment option for the treatment of lung cancer, it is not suitable for all patients. Patients need to pay attention to some contraindications when using capmatinib to ensure drug safety and reduce the occurrence of side effects.

1. Patients allergic to capmatinib or any of its components

One of the contraindications to capmatinib is allergy to any component of the drug. Allergic reactions may manifest as rash, shortness of breath, swelling of the face or throat, asthma symptoms, and more. Patients should avoid using capmatinib if they have had an allergic reaction to it or any of its components (such as excipients). Allergic reactions may cause serious complications, such as anaphylactic shock, difficulty breathing, etc. Therefore, once allergic symptoms occur, you should stop using it immediately and seek medical help.

2. Contraindications during pregnancy

Capmatinib is a drug that may cause harm to the fetus, so its use during pregnancy is contraindicated. Studies have shown that the safety of capmatinib in pregnant women has not been fully evaluated and may have adverse effects on fetal growth and development. Capmatinib belongs to the FDA's category D drugs, which means that use during pregnancy may cause harm to the fetus. If a patient becomes pregnant or plans to become pregnant, alternative treatment options should be discussed with the physician and capmatinib should be discontinued immediately.

3. Contraindications during breastfeeding

Capmatinib also poses risks to breastfeeding women. Although it is not known whether capmatinib passes into breast milk, nursing women should avoid using capmatinib because of the potential risk to the baby. If the patient is breastfeeding, breastfeeding should be stopped before starting capmatinib to prevent the drug from being passed to the baby through breast milk, which may cause adverse reactions.

4. Patients with severe liver dysfunction

Capmatinib is metabolized primarily by the liver; therefore, patients with hepatic impairment require special caution when using capmatinib. If patients have severe liver dysfunction (such as cirrhosis or severe hepatitis), capmatinib should be avoided or the dosage should be adjusted under the guidance of a physician. Abnormal liver function may affect the metabolism of capmatinib, causing the drug to accumulate in the body and increasing the risk of toxicity. During the treatment process, liver function needs to be monitored regularly. If abnormal liver function is found, the medication regimen should be adjusted in time or treatment should be suspended.

5. Patients with severe lung disease in the past

Capmatinib may cause lung-related adverse reactions, especially interstitial lung disease (ILD) or pneumonia. Use of capmatinib may increase the risk of pulmonary complications if the patient has a history of severe lung disease before or during treatment. Side effects of capmatinib include, but are not limited to, pulmonary symptoms such as persistent cough, difficulty breathing, chest pain, or fever. If the patient has a history of interstitial lung disease or other severe lung disease, capmatinib should be used with special caution and under the close supervision of a physician.

6. Patients with severe renal insufficiency

Although the main metabolic pathway of capmatinib is through the liver, it should be used with caution in patients with renal insufficiency. When patients receive capmatinib treatment, renal insufficiency may affect the metabolism and excretion of the drug, resulting in excessive drug concentration in the body. For patients with severely impaired renal function, capmatinib should be avoided or the dose should be adjusted under the guidance of a physician.

7. Contraindications for the combined use of with CYP3A4strong inhibitors

Capmatinib is metabolized by the liver's CYP3A4 enzyme system. Therefore, during the use of capmatinib, avoid combined use with strong CYP3A4 inhibitors (such as certain antifungal drugs, antibiotics, HIV drugs, etc.). StrongCYP3A4inhibitors may increase the plasma concentration of capmatinib, thereby increasing its risk of toxicity. While taking capmatinib, patients need to confirm with their doctor whether there is any drug interaction, and try to avoid using CYP3A4 inhibitors or adjust drug dosage.

8. Contraindicated in undiagnosed patientsMETUse in patients with mutations

Capmatinib is only suitable for patients with non-small cell lung cancer (NSCLC) who have METexon14 skipping mutations (METex14) or MET amplification. Patients should undergo relevant genetic testing to confirm the presence of the above-mentioned mutations or amplifications before starting capmatinib treatment. Patients without MET mutations may not achieve the expected therapeutic effect with capmatinib and may be at increased risk of side effects. Therefore, capmatinib should not be used in patients with non-small cell lung cancer who do not have a MET mutation.

9. Contraindications for combined use with other targeted drugs

In some cases, coadministration of capmatinib with other targeted therapies may result in drug-drug interactions and increase the risk of side effects. For example, when used in combination with certain other drugs that inhibit the MET pathway or drugs that interfere with liver metabolism, concurrent use of capmatinib should be avoided, or the dosage should be adjusted under the guidance of a physician.

Capmatinib is a targeted drug used to treat non-small cell lung cancer, but during use, patients need to follow strict contraindications to ensure the safety and effectiveness of the drug. Patients should be particularly careful in pregnancy, breastfeeding, severe liver dysfunction, lung disease, and drug interactions. Patients should fully communicate with their doctors to ensure the safety and effectiveness of drug use.

xa0

Reference materials

1.FDA Capmatinib Approval Information -

https://www.fda.gov/drugs/drug-approvals-and-databases/tabrecta-capmatinib

2.Novartis Capmatinib Product Information - https://www.novartis.com/

3.ClinicalTrials.gov Study Details for Capmatinib -

https://clinicaltrials.gov/ct2/show/NCT02414139